LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Kodu・Aktsiate loetelu・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Suletud

SektorTervishoid

0.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.17

Max

0.17

Põhinäitajad
By Trading Economics
Sissetulek	-2.5M -37M
Müük	14M 14M
Aktsiakasum	-0.111
Kasumimarginaal	-262.996
Töötajad	142
EBITDA	10M -23M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+4515.38% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-51M 74M
Eelmine avamishind	0.17
Eelmine sulgemishind	0.17

Uudiste sentiment

By Acuity

50%

187 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.5207 / 0.7223 Toetus ja vastupanu

Sangamo Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. mai 2026, 23:41 UTC

Tulu

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. mai 2026, 21:40 UTC

Tulu

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. mai 2026, 23:13 UTC

Tulu

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. mai 2026, 23:12 UTC

Tulu

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. mai 2026, 23:11 UTC

Tulu

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. mai 2026, 23:11 UTC

Tulu

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. mai 2026, 23:07 UTC

Tulu

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. mai 2026, 23:06 UTC

Tulu

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. mai 2026, 23:05 UTC

Tulu

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. mai 2026, 23:04 UTC

Tulu

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. mai 2026, 22:50 UTC

Tulu

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. mai 2026, 22:11 UTC

Tulu

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. mai 2026, 21:58 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:47 UTC

Market Talk

Tulu

Costco Posts 13% Sales Growth in April -- Market Talk

6. mai 2026, 21:46 UTC

Tulu

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. mai 2026, 21:40 UTC

Tulu

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. mai 2026, 21:32 UTC

Kuumad aktsiad

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. mai 2026, 21:29 UTC

Tulu

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sangamo Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

4515.38% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 4515.38%

Kõrge 10 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Sangamo Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Sangamo Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5207 / 0.7223Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

187 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.